| References |
| 1. | Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev 88: 389‐419, 2008. |
| 2. | Ahmad FS, Ning H, Rich JD, Yancy CW, Lloyd‐Jones DM, Wilkins JT. Hypertension, obesity, diabetes, and heart failure‐free survival: The cardiovascular disease lifetime risk pooling project. JACC Heart Fail 4: 911‐919, 2016. |
| 3. | Al‐Solaiman Y, Jesri A, Mountford WK, Lackland DT, Zhao Y, Egan BM. DASH lowers blood pressure in obese hypertensives beyond potassium, magnesium and fibre. J Hum Hypertens 24: 237‐246, 2010. |
| 4. | Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC, Jr., International Diabetes Federation Task Force on E, Prevention, Hational Heart L, Blood I, American Heart A, World Heart F, International Atherosclerosis S, and International Association for the Study of O. Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640‐1645, 2009. |
| 5. | Alpert MA, Lambert CR, Panayiotou H, Terry BE, Cohen MV, Massey CV, Hashimi MW, Mukerji V. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 76: 1194‐1197, 1995. |
| 6. | Amy RM, Dolphin PJ, Pederson RA, Russell JC. Atherogenesis in two strains of obese rats. The fatty Zucker and LA/N‐corpulent. Atherosclerosis 69: 199‐209, 1988. |
| 7. | Ander BP, Dupasquier CM, Prociuk MA, Pierce GN. Polyunsaturated fatty acids and their effects on cardiovascular disease. Exp Clin Cardiol 8: 164‐172, 2003. |
| 8. | Aurigemma GP, de Simone G, Fitzgibbons TP. Cardiac remodeling in obesity. Circ Cardiovasc Imaging 6: 142‐152, 2013. |
| 9. | Barger PM, Brandt JM, Leone TC, Weinheimer CJ, Kelly DP. Deactivation of peroxisome proliferator‐activated receptor‐alpha during cardiac hypertrophic growth. J Clin Invest 105: 1723‐1730, 2000. |
| 10. | Barger PM, Kelly DP. PPAR signaling in the control of cardiac energy metabolism. Trends Cardiovasc Med 10: 238‐245, 2000. |
| 11. | Barrett SJ. The role of omega‐3 polyunsaturated fatty acids in cardiovascular health. Altern Ther Health Med 19(Suppl 1): 26‐30, 2013. |
| 12. | Bates SH, Kulkarni RN, Seifert M, Myers MG, Jr. Roles for leptin receptor/STAT3‐dependent and ‐independent signals in the regulation of glucose homeostasis. Cell Metab 1: 169‐178, 2005. |
| 13. | Bates SH, Stearns WH, Dundon TA, Schubert M, Tso AW, Wang Y, Banks AS, Lavery HJ, Haq AK, Maratos‐Flier E, Neel BG, Schwartz MW, Myers MG, Jr. STAT3 signalling is required for leptin regulation of energy balance but not reproduction. Nature 421: 856‐859, 2003. |
| 14. | Blalock JE. The immune system as the sixth sense. J Intern Med 257: 126‐138, 2005. |
| 15. | Blasbalg TL, Hibbeln JR, Ramsden CE, Majchrzak SF, Rawlings RR. Changes in consumption of omega‐3 and omega‐6 fatty acids in the United States during the 20th century. Am J Clin Nutr 93: 950‐962, 2011. |
| 16. | Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, Caccia C, Johnson J, Waugh R, Sherwood A. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: The ENCORE study. Arch Intern Med 170: 126‐135, 2010. |
| 17. | Bozkurt B, Kribbs SB, Clubb FJ, Jr., Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor‐alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation 97: 1382‐1391, 1998. |
| 18. | Brainard RE, Watson LJ, Demartino AM, Brittian KR, Readnower RD, Boakye AA, Zhang D, Hoetker JD, Bhatnagar A, Baba SP, Jones SP. High fat feeding in mice is insufficient to induce cardiac dysfunction and does not exacerbate heart failure. PloS One 8: e83174, 2013. |
| 19. | Bray GA, York DA. Hypothalamic and genetic obesity in experimental animals: An autonomic and endocrine hypothesis. Physiol Rev 59: 719‐809, 1979. |
| 20. | Chandler MP, Morgan EE, McElfresh TA, Kung TA, Rennison JH, Hoit BD, Young ME. Heart failure progression is accelerated following myocardial infarction in type 2 diabetic rats. Am J Physiol Heart Circ Physiol 293: H1609‐H1616, 2007. |
| 21. | Chen YT, Vaccarino V, Williams CS, Butler J, Berkman LF, Krumholz HM. Risk factors for heart failure in the elderly: A prospective community‐based study. Am J Med 106: 605‐612, 1999. |
| 22. | Chrysohoou C, Pitsavos C, Metallinos G, Antoniou C, Oikonomou E, Kotroyiannis I, Tsantilas A, Tsitsinakis G, Tousoulis D, Panagiotakos DB, Stefanadis C. Cross‐sectional relationship of a Mediterranean type diet to diastolic heart function in chronic heart failure patients. Heart Vessels 27: 576‐584, 2012. |
| 23. | Chua SC, Jr., Chung WK, Wu‐Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science (New York, NY) 271: 994‐996, 1996. |
| 24. | Coleman DL. Obese and diabetes: Two mutant genes causing diabetes‐obesity syndromes in mice. Diabetologia 14: 141‐148, 1978. |
| 25. | Crouse JA, Elliott GE, Burgess TL, Chiu L, Bennett L, Moore J, Nicolson M, Pacifici RE. Altered cell surface expression and signaling of leptin receptors containing the fatty mutation. J Biol Chem 273: 18365‐18373, 1998. |
| 26. | da Silva BA, Bjorbaek C, Uotani S, Flier JS. Functional properties of leptin receptor isoforms containing the gln→pro extracellular domain mutation of the fatty rat. Endocrinology 139: 3681‐3690, 1998. |
| 27. | de Castro Bras LE, Cates CA, Deleon‐Pennell KY, Ma Y, Iyer RP, Halade GV, Yabluchanskiy A, Fields GB, Weintraub ST, Lindsey ML. Citrate synthase is a novel in vivo matrix metalloproteinase‐9 substrate that regulates mitochondrial function in the post‐myocardial infarction left ventricle. Antioxid Redox Signal 21: 1974‐1985, 2014. |
| 28. | de Castro Bras LE, Ramirez TA, DeLeon‐Pennell KY, Chiao YA, Ma Y, Dai Q, Halade GV, Hakala K, Weintraub ST, Lindsey ML. Texas 3‐step decellularization protocol: Looking at the cardiac extracellular matrix. J Proteomics 86: 43‐52, 2013. |
| 29. | De Caterina R. n‐3 fatty acids in cardiovascular disease. N Engl J Med 364: 2439‐2450, 2011. |
| 30. | de Oliveira Otto MC, Wu JH, Baylin A, Vaidya D, Rich SS, Tsai MY, Jacobs DR, Jr., Mozaffarian D. Circulating and dietary omega‐3 and omega‐6 polyunsaturated fatty acids and incidence of CVD in the Multi‐Ethnic Study of Atherosclerosis. J Am Heart Assoc 2: e000506, 2013. |
| 31. | de Pablo MA, Alvarez de Cienfuegos G. Modulatory effects of dietary lipids on immune system functions. Immunol Cell Biol 78: 31‐39, 2000. |
| 32. | Del Gobbo LC, Imamura F, Aslibekyan S, Marklund M, Virtanen JK, Wennberg M, Yakoob MY, Chiuve SE, Dela Cruz L, Frazier‐Wood AC, Fretts AM, Guallar E, Matsumoto C, Prem K, Tanaka T, Wu JH, Zhou X, Helmer C, Ingelsson E, Yuan JM, Barberger‐Gateau P, Campos H, Chaves PH, Djousse L, Giles GG, Gomez‐Aracena J, Hodge AM, Hu FB, Jansson JH, Johansson I, Khaw KT, Koh WP, Lemaitre RN, Lind L, Luben RN, Rimm EB, Riserus U, Samieri C, Franks PW, Siscovick DS, Stampfer M, Steffen LM, Steffen BT, Tsai MY, van Dam RM, Voutilainen S, Willett WC, Woodward M, Mozaffarian D. Omega‐3 polyunsaturated fatty acid biomarkers and coronary heart disease: Pooling project of 19 cohort studies. JAMA Intern Med 176: 1155‐1166, 2016. |
| 33. | Delgado‐Lista J, Perez‐Martinez P, Lopez‐Miranda J, Perez‐Jimenez F. Long chain omega‐3 fatty acids and cardiovascular disease: A systematic review. Br J Nutr 107(Suppl 2): S201‐S213, 2012. |
| 34. | Dhana K, Koolhaas CM, van Rossum EFC, Ikram MA, Hofman A, Kavousi M, Franco OH. Metabolically healthy obesity and the risk of cardiovascular disease in the elderly population. PloS One 11: e0154273, 2016. |
| 35. | Dick SA, Epelman S. Chronic heart failure and inflammation: What do we really know? Circ Res 119: 159‐176, 2016. |
| 36. | Diwan A, Dibbs Z, Nemoto S, DeFreitas G, Carabello BA, Sivasubramanian N, Wilson EM, Spinale FG, Mann DL. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation 109: 262‐268, 2004. |
| 37. | Doehner W, Clark A, Anker SD. The obesity paradox: Weighing the benefit. Eur Heart J 31: 146‐148, 2010. |
| 38. | Eilat‐Adar S, Sinai T, Yosefy C, Henkin Y. Nutritional recommendations for cardiovascular disease prevention. Nutrients 5: 3646‐3683, 2013. |
| 39. | Estruch R, Ros E, Salas‐Salvado J, Covas MI, Corella D, Aros F, Gomez‐Gracia E, Ruiz‐Gutierrez V, Fiol M, Lapetra J, Lamuela‐Raventos RM, Serra‐Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez‐Gonzalez MA, Investigators PS. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368: 1279‐1290, 2013. |
| 40. | Evans RM, Barish GD, Wang Y‐X. PPARs and the complex journey to obesity. Nat Med 10: 355‐361, 2004. |
| 41. | Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110: 1093‐1103, 2002. |
| 42. | Fezeu LK, Laporte F, Kesse‐Guyot E, Andreeva VA, Blacher J, Hercberg S, Galan P. Baseline plasma fatty acids profile and incident cardiovascular events in the SU.FOL.OM3 trial: The evidence revisited. PloS One 9: e92548, 2014. |
| 43. | Figlewicz DP, Ikeda H, Hunt TR, Stein LJ, Dorsa DM, Woods SC, Porte D, Jr. Brain insulin binding is decreased in Wistar Kyoto rats carrying the ‘fa’ gene. Peptides 7: 61‐65, 1986. |
| 44. | Finck BN, Lehman JJ, Barger PM, Kelly DP. Regulatory networks controlling mitochondrial energy production in the developing, hypertrophied, and diabetic heart. Cold Spring Harb Symp Quant Biol 67: 371‐382, 2002. |
| 45. | Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999‐2010. JAMA 307: 491‐497, 2012. |
| 46. | Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 11: 255‐265, 2014. |
| 47. | Friedman DJ, Wang N, Meigs JB, Hoffmann U, Massaro JM, Fox CS, Magnani JW. Pericardial fat is associated with atrial conduction: The Framingham Heart Study. J Am Heart Assoc 3: e000477, 2014. |
| 48. | Fullerton JN, Gilroy DW. Resolution of inflammation: A new therapeutic frontier. Nat Rev Drug Discov 15: 551‐567, 2016. |
| 49. | Gray SL, Dalla Nora E, Vidal‐Puig AJ. Mouse models of PPAR‐γ deficiency: Dissecting PPAR‐γ’s role in metabolic homoeostasis. Biochem Soc Trans 33: 1053‐1058, 2005. |
| 50. | Halade GV, El Jamali A, Williams PJ, Fajardo RJ, Fernandes G. Obesity‐mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. Exp Gerontol 46: 43‐52, 2011. |
| 51. | Halade GV, Kain V, Black LM, Prabhu SD, Ingle KA. Aging dysregulates D‐ and E‐series resolvins to modulate cardiosplenic and cardiorenal network following myocardial infarction. Aging (Albany NY) 8: 2611‐2634, 2016. |
| 52. | Halade GV, Ma Y, Ramirez TA, Zhang J, Dai Q, Hensler JG, Lopez EF, Ghasemi O, Jin YF, Lindsey ML. Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 305: H1830‐H1842, 2013. |
| 53. | Halade GV, Rahman MM, Williams PJ, Fernandes G. High fat diet‐induced animal model of age‐associated obesity and osteoporosis. J Nutr Biochem 21: 1162‐1169, 2010. |
| 54. | Halade GV, Rahman MM, Williams PJ, Fernandes G. Combination of conjugated linoleic acid with fish oil prevents age‐associated bone marrow adiposity in #c57Bl/6J mice. J Nutr Biochem 22: 459‐469, 2011. |
| 55. | Hall JA, French TK, Rasmusson KD, Vesty JC, Roberts CA, Rimmasch HL, Kfoury AG, Renlund DG. The paradox of obesity in patients with heart failure. J Am Acad Nurse Pract 17: 542‐546, 2005. |
| 56. | Hassan Eftekhari M, Aliasghari F, Babaei‐Beigi MA, Hasanzadeh J. Effect of conjugated linoleic acid and omega‐3 fatty acid supplementation on inflammatory and oxidative stress markers in atherosclerotic patients. ARYA Atheroscler 9: 311‐318, 2013. |
| 57. | He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM. Adipose‐specific peroxisome proliferator‐activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A 100: 15712‐15717, 2003. |
| 58. | Heaberlin JR, Ma Y, Zhang J, Ahuja SS, Lindsey ML, Halade GV. Obese and diabetic KKAy mice show increased mortality but improved cardiac function following myocardial infarction. Cardiovasc Pathol 22: 481‐487, 2013. |
| 59. | Hill JO, Wyatt HR. The myth of healthy obesity. Ann Intern Med 159: 789‐790, 2013. |
| 60. | Hood WB, Jr., McCarthy B, Lown B. Myocardial infarction following coronary ligation in dogs. Hemodynamic effects of isoproterenol and acetylstrophanthidin. Circ Res 21: 191‐199, 1967. |
| 61. | Horwich TB, Fonarow GC. The impact of obesity on survival in patients with heart failure. Heart Fail Monit 3: 8‐14, 2002. |
| 62. | Howes LG. Selective COX‐2 inhibitors, NSAIDs and cardiovascular events—is celecoxib the safest choice? Ther Clin Risk Manag 3: 831‐845, 2007. |
| 63. | Huang H, Amin V, Gurin M, Wan E, Thorp E, Homma S, Morrow JP. Diet‐induced obesity causes long QT and reduces transcription of voltage‐gated potassium channels. J Mol Cell Cardiol 59: 151‐158, 2013. |
| 64. | Hummel SL, Seymour EM, Brook RD, Sheth SS, Ghosh E, Zhu S, Weder AB, Kovacs SJ, Kolias TJ. Low‐sodium DASH diet improves diastolic function and ventricular‐arterial coupling in hypertensive heart failure with preserved ejection fraction. Circ Heart Fail 6: 1165‐1171, 2013. |
| 65. | Ingle KA, Kain V, Goel M, Prabhu SD, Young ME, Halade GV. Cardiomyocyte specific Bmal1 deletion in mice triggers diastolic dysfunction, extracellular matrix response and impaired resolution of inflammation. Am J Physiol Heart Circ Physiol 309: H1827‐H1836, 2015. |
| 66. | Johnson AR, Milner JJ, Makowski L. The inflammation highway: Metabolism accelerates inflammatory traffic in obesity. Immunol Rev 249: 218‐238, 2012. |
| 67. | Jones SP, Girod WG, Granger DN, Palazzo AJ, Lefer DJ. Reperfusion injury is not affected by blockade of P‐selectin in the diabetic mouse heart. Am J Physiol 277: H763‐H769, 1999. |
| 68. | Jung UJ, Choi MS. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci 15: 6184‐6223, 2014. |
| 69. | Kain V, Prabhu SD, Halade GV. Inflammation revisited: Inflammation versus resolution of inflammation following myocardial infarction. Basic Res Cardiol 109: 444, 2014. |
| 70. | Kar S. Role of omega‐3 fatty acids in the prevention of atrial fibrillation. Rev Cardiovasc Med 14: e82‐e91, 2013. |
| 71. | Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med 347: 305‐313, 2002. |
| 72. | Krakauer NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PloS One 7: e39504, 2012. |
| 73. | Lawrence GD. Dietary fats and health: Dietary recommendations in the context of scientific evidence. Adv Nutr 4: 294‐302, 2013. |
| 74. | Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, Gibson MF, Lefer AM. HMG‐CoA reductase inhibition protects the diabetic myocardium from ischemia‐reperfusion injury. FASEB J 15: 1454‐1456, 2001. |
| 75. | Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. Arch Intern Med 169: 851‐857, 2009. |
| 76. | Lin PH, Yeh WT, Svetkey LP, Chuang SY, Chang YC, Wang C, Pan WH. Dietary intakes consistent with the DASH dietary pattern reduce blood pressure increase with age and risk for stroke in a Chinese population. Asia Pac J Clin Nutr 22: 482‐491, 2013. |
| 77. | Lissin LW, Gauri AJ, Froelicher VF, Ghayoumi A, Myers J, Giacommini J. The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. J Card Fail 8: 206‐215, 2002. |
| 78. | Lopez EF, Kabarowski JH, Ingle KA, Kain V, Barnes S, Crossman DK, Lindsey ML, Halade GV. Obesity superimposed on aging magnifies inflammation and delays the resolving response after myocardial infarction. Am J Physiol Heart Circ Physiol 308: H269‐H280, 2015. |
| 79. | Marangoni F, Novo G, Perna G, Perrone Filardi P, Pirelli S, Ceroti M, Querci A, Poli A. Omega‐6 and omega‐3 polyunsaturated fatty acid levels are reduced in whole blood of Italian patients with a recent myocardial infarction: The AGE‐IM study. Atherosclerosis 232: 334‐338, 2014. |
| 80. | Martin SS, Qasim A, Reilly MP. Leptin resistance: A possible interface of inflammation and metabolism in obesity‐related cardiovascular disease. J Am Coll Cardiol 52: 1201‐1210, 2008. |
| 81. | Martinez‐Gonzalez MA, Bes‐Rastrollo M. Dietary patterns, Mediterranean diet, and cardiovascular disease. Curr Opin Lipidol 25: 20‐26, 2014. |
| 82. | Mayer J, Bates MW, Dickie MM. Hereditary diabetes in genetically obese mice. Science (New York, NY) 113: 746‐747, 1951. |
| 83. | Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A, Grobbee DE. The prognosis of heart failure in the general population: The Rotterdam Study. Eur Heart J 22: 1318‐1327, 2001. |
| 84. | Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk a systematic review and meta‐analysis. J Am Coll Cardiol 56: 1113‐1132, 2010. |
| 85. | Mozaffarian D, Wu JH. Omega‐3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58: 2047‐2067, 2011. |
| 86. | Nguyen KD, Fentress SJ, Qiu Y, Yun K, Cox JS, Chawla A. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science (New York, NY) 341: 1483‐1488, 2013. |
| 87. | O'Brien EC, Fosbol EL, Peng SA, Alexander KP, Roe MT, Peterson ED. Association of body mass index and long‐term outcomes in older patients with non‐ST‐segment‐elevation myocardial infarction: Results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes 7: 102‐109, 2014. |
| 88. | Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL, Group SS. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 25: 342‐348, 2004. |
| 89. | Oltman CL, Richou LL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Progression of coronary and mesenteric vascular dysfunction in Zucker obese and Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 291: H1780‐H1787, 2006. |
| 90. | Phillips CM. Metabolically healthy obesity: Definitions, determinants and clinical implications. Rev Endocr Metab Disord 14: 219‐227, 2013. |
| 91. | Poncelas M, Inserte J, Vilardosa U, Rodriguez‐Sinovas A, Baneras J, Simo R, Garcia‐Dorado D. Obesity induced by high fat diet attenuates postinfarct myocardial remodeling and dysfunction in adult B6D2F1 mice. J Mol Cell Cardiol 84: 154‐161, 2015. |
| 92. | Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, Jaarsma T, Krum H, Rastogi V, Rohde LE, Samal UC, Shimokawa H, Budi Siswanto B, Sliwa K, Filippatos G. Heart failure: Preventing disease and death worldwide. ESC Heart Fail 1: 4‐25, 2014. |
| 93. | Praticò D, Dogné J‐M. Selective cyclooxygenase‐2 inhibitors development in cardiovascular medicine. Circulation 112: 1073‐1079, 2005. |
| 94. | Punchard NA, Whelan CJ, Adcock I. The journal of inflammation. J Inflamm (Lond) 1(1): 1, 2004.
|
| 95. | Rees K, Hartley L, Flowers N, Clarke A, Hooper L, Thorogood M, Stranges S. ‘Mediterranean’ dietary pattern for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 8: CD009825, 2013. |
| 96. | Remondino A, Rosenblatt‐Velin N, Montessuit C, Tardy I, Papageorgiou I, Dorsaz PA, Jorge‐Costa M, Lerch R. Altered expression of proteins of metabolic regulation during remodeling of the left ventricle after myocardial infarction. J Mol Cell Cardiol 32: 2025‐2034, 2000. |
| 97. | Riquelme CA, Magida JA, Harrison BC, Wall CE, Marr TG, Secor SM, Leinwand LA. Fatty acids identified in the Burmese python promote beneficial cardiac growth. Science (New York, NY) 334: 528‐531, 2011. |
| 98. | Rockman HA, Ross RS, Harris AN, Knowlton KU, Steinhelper ME, Field LJ, Ross J, Jr., Chien KR. Segregation of atrial‐specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci U S A 88: 8277‐8281, 1991. |
| 99. | Sala‐Vila A, Guasch‐Ferre M, Hu FB, Sanchez‐Tainta A, Bullo M, Serra‐Mir M, Lopez‐Sabater C, Sorli JV, Aros F, Fiol M, Munoz MA, Serra‐Majem L, Martinez JA, Corella D, Fito M, Salas‐Salvado J, Martinez‐Gonzalez MA, Estruch R, Ros E. Dietary alpha‐linolenic acid, marine omega‐3 fatty acids, and mortality in a population with high fish consumption: Findings from the PREvencion con DIeta MEDiterranea (PREDIMED) Study. J Am Heart Assoc 5: pii: e002543, 2016. |
| 100. | Salehi‐Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)‐style diet on fatal or nonfatal cardiovascular diseases–incidence: A systematic review and meta‐analysis on observational prospective studies. Nutrition 29: 611‐618, 2013. |
| 101. | Salter AM. Dietary fatty acids and cardiovascular disease. Animal 7(Suppl 1): 163‐171, 2013. |
| 102. | Schargrodsky H, Rozlosnik J, Ciruzzi M, Ruffa R, Paterno C, Ardariz M, Caccavo A, D'Avanzo B, Negri E, La Vecchia C, et al. Body weight and nonfatal myocardial infarction in a case‐control study from Argentina. Soz Praventivmed 39: 126‐133, 1994. |
| 103. | Stanley WC, Dabkowski ER, Ribeiro RF, Jr., O'Connell KA. Dietary fat and heart failure: Moving from lipotoxicity to lipoprotection. Circ Res 110: 764‐776, 2012. |
| 104. | Stepien M, Stepien A, Wlazel RN, Paradowski M, Banach M, Rysz J. Obesity indices and inflammatory markers in obese non‐diabetic normo‐ and hypertensive patients: A comparative pilot study. Lipids Health Dis 13: 29, 2014. |
| 105. | Stepien M, Wlazel RN, Paradowski M, Banach M, Rysz M, Misztal M, Rysz J. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo‐ and hypertensive patients—pilot study. Arch Med Sci 8: 431‐436, 2012. |
| 106. | Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of n‐3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI‐HF trial): A randomised, double‐blind, placebo‐controlled trial. Lancet 372: 1223‐1230, 2008. |
| 107. | Thakker GD, Frangogiannis NG, Bujak M, Zymek P, Gaubatz JW, Reddy AK, Taffet G, Michael LH, Entman ML, Ballantyne CM. Effects of diet‐induced obesity on inflammation and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol 291: H2504‐H2514, 2006. |
| 108. | Thomsen M, Nordestgaard BG. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern Med 174: 15‐22, 2013. |
| 109. | Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western‐lifestyle” inflammatory diseases. Immunity 40: 833‐842, 2014. |
| 110. | Thorvaldsen T, Benson L, Stahlberg M, Dahlstrom U, Edner M, Lund LH. Triage of patients with moderate to severe heart failure: Who should be referred to a heart failure center? J Am Coll Cardiol 63: 661‐671, 2014. |
| 111. | Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: A quantitative systematic review. Obes Rev 12: 50‐61, 2011. |
| 112. | van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the failing heart: The cardiac burn‐out syndrome? Cardiovasc Res 61: 218‐226, 2004. |
| 113. | van den Tweel JG, Taylor CR. A brief history of pathology: Preface to a forthcoming series that highlights milestones in the evolution of pathology as a discipline. Virchows Arch 457: 3‐10, 2010. |
| 114. | Van Horn L, Yancy C. Diet prevention and therapy for heart failure? Circ Heart Fail 6: 1109‐1111, 2013. |
| 115. | Viola J, Soehnlein O. Atherosclerosis—a matter of unresolved inflammation. Semin Immunol 27: 184‐193, 2015. |
| 116. | Wang B, Chandrasekera PC, Pippin JJ. Leptin‐ and leptin receptor‐deficient rodent models: Relevance for human type 2 diabetes. Curr Diabetes Rev 10: 131‐145, 2014. |
| 117. | Wang F, Mullican SE, DiSpirito JR, Peed LC, Lazar MA. Lipoatrophy and severe metabolic disturbance in mice with fat‐specific deletion of PPARgamma. Proc Natl Acad Sci U S A 110: 18656‐18661, 2013. |
| 118. | Wendel AA, Belury MA. Effects of conjugated linoleic acid and troglitazone on lipid accumulation and composition in lean and Zucker diabetic fatty (fa/fa) rats. Lipids 41: 241‐247, 2006. |
| 119. | Wilbring M, Ploetze K, Bormann S, Waldow T, Matschke K. Omega‐3 polyunsaturated fatty acids reduce the incidence of postoperative atrial fibrillation in patients with history of prior myocardial infarction undergoing isolated coronary artery bypass grafting. Thorac Cardiovasc Surg 62: 56‐574, 2014. |
| 120. | Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men–‐morbidity, risk factors and prognosis. J Intern Med 249: 253‐261, 2001. |
| 121. | Wood KE, Lau A, Mantzioris E, Gibson RA, Ramsden CE, Muhlhausler BS. A low omega‐6 polyunsaturated fatty acid (n‐6 PUFA) diet increases omega‐3 (n‐3) long chain PUFA status in plasma phospholipids in humans. Prostaglandins Leukot Essent Fatty Acids 90: 133‐138, 2014. |
| 122. | Yue TL, Bao W, Gu JL, Cui J, Tao L, Ma XL, Ohlstein EH, Jucker BM. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion‐induced myocardial injury. Diabetes 54: 554‐562, 2005. |
| 123. | Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 372: 425‐432, 1994. |
| 124. | Zhu J, Su X, Li G, Chen J, Tang B, Yang Y. The incidence of acute myocardial infarction in relation to overweight and obesity: A meta‐analysis. Arch Med Sci 10: 855‐862, 2014. |
| 125. | Zierath JR, Ryder JW, Doebber T, Woods J, Wu M, Ventre J, Li Z, McCrary C, Berger J, Zhang B, Moller DE. Role of skeletal muscle in thiazolidinedione insulin sensitizer (PPARgamma agonist) action. Endocrinology 139: 5034‐5041, 1998. |
